Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Item

http://www.wikidata.org/entity/Q28282755

Q28282755

about

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Progress toward overcoming hypoxia-induced resistance to solid tumor therapy The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck HypoxamiRs and cancer: from biology to targeted therapy Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.In vivo optimisation study for multi-baseline MR-based thermometry in the context of hyperthermia using MR-guided high intensity focused ultrasound for head and neck applications.Solid MRI contrast agents for long-term, quantitative in vivo oxygen sensing.ABC transporters in CSCs membranes as a novel target for treating tumor relapse.Targeting hypoxic tumour cells to overcome metastasis.Molecular radiobiology: the state of the art Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin.Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors Personalized radiotherapy: concepts, biomarkers and trial design Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis Systemic therapy strategies for head-neck carcinomas: Current status Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.Magnetic resonance-guided high-intensity focused ultrasound combined with radiotherapy for palliation of head and neck cancer-a pilot study Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review New paradigms and future challenges in radiation oncology: an update of biological targets and technology.18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model Targeting the metabolic microenvironment of tumors.Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.Quality assurance for clinical trials Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.Strategies for optimizing the response of cancer and normal tissues to radiation.Radiotherapy quality assurance report from children's oncology group AHOD0031

P2860

Q24235245-D236ECEC-B7AD-4D92-9933-87335FFA465F Q24651122-9C8F649E-D2DB-49F7-995C-CB90BB5E5143 Q26774750-12F2272A-EFFD-4470-8C4A-B6A99F007111 Q26796405-31E5457B-33C9-4315-8F93-E40DA115A1E2 Q26830495-1A4D6A59-1C7D-41FF-BC04-80F8CC971569 Q26863298-C79E0011-DA9F-419C-918C-3B0A0E8AC318 Q27009437-D4AD1F4F-427D-41A2-9790-CB83918BC99D Q27025579-497D123D-441B-432F-95A5-729422DC8747 Q28085180-5C085074-F101-47DB-B551-E04780265D8C Q28301587-3CCFAF48-37D1-4C0B-9C8B-E1DDD8728B24 Q30408170-54555311-2BA6-4A03-87A5-DC6565104FCF Q30872312-C4EF5E7D-2385-423B-9580-B64F1155B23E Q33607091-BC8A668F-445A-4BEC-BDF3-F42BEAF52FE6 Q33879326-397661A6-EE24-4B44-A0AB-7259F4D26556 Q34086671-A63503EB-2CEC-459A-B38B-B3CF741AA7F9 Q34124274-7ECEE9EC-05E8-4A49-ABB4-67B846DE6B70 Q34193953-B5BDD1E9-CB7B-4234-93F5-6CD7D357C3D9 Q34756921-01CCD3B1-5F66-445D-8224-426EFEB528CB Q35034825-036325C5-1775-4D42-A7C6-712AD9E8C8DB Q35652920-FA75FE3A-727A-4C8B-B92E-3C2113CB8BFF Q35836427-220E3614-E230-4070-B23D-AC2FB6806EAA Q36079855-3F51FBB9-F2D3-42E7-A6CD-5D9D55E38B0E Q36235704-A1E8D403-9BA0-4C52-B4A7-06BA72101754 Q36378279-6C158BD0-AB24-4BFC-9E88-6756D718F635 Q36507559-7B2E5ADA-C773-457A-8979-0D7BB77B0925 Q36516789-D38E90A8-D589-4982-AD22-86F56F074D2A Q36529843-974D459A-2426-4E34-A6F9-38F01712B241 Q36619504-88BB63A0-F2A1-4CBE-84F9-2B43A8FC13DE Q36759883-1C451D3D-F49E-42B6-881F-24F9628622BE Q37110377-2463D8F9-52AF-4A8D-9592-E6470315A605 Q37160539-F7A2F404-5586-4C34-BA47-6B536A45E777 Q37165297-05DAEC39-3BD7-40FE-A300-AE631AFEFEFC Q37170729-395AE27C-EE54-46A6-B68C-B9C9A0693CDA Q37229190-D1CCFA0C-672F-49FE-8558-5ABA0A13E2F3 Q37242284-9A9EB326-2A24-40B9-BA78-26BDE9300D51 Q37369324-FD984BED-13D5-47D7-8574-4DB44A0B5E5E Q37402633-526125EF-0A73-4733-BAA9-AAFD45526DB0 Q37415654-9B5344D5-11CE-49BF-961C-18978F512122 Q37531724-7C116931-723F-4966-9755-70EFAC5E308B Q37590108-BF9AFA24-6B69-40A4-BE1B-8C787301BF6E

P2860

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Item

http://www.wikidata.org/entity/Q28282755

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu